ProdUct nEWS
hEdrIn LaUnchES monEY bacK gUarantEE market leader in the head lice category, hedrin, has launched a new money back guarantee this summer to run until the end of September. ‘happy with hedrin or your money back’ allows parents to claim a full refund if they are not satisfied with the product. the offer follows work by the brand to simplify its packaging following research into the needs and preferences of mums. the brand continues to thrive and is currently the most recalled product in the head lice category according to independent research commissioned by thornton & ross. hedrin once was recently put to the test on the Itv show ‘Save money: good health’ where the product was compared with other head lice brands and was judged to be ‘most effective’ and ‘best value’ treatment by an independent expert. for more information, visit
www.hedrin.co.uk or contact thornton & ross on 01484 842217.
ExtEndEd coSt SavIngS WIth addItIon of nEW
40g anabact 0.75% W/W gEL (mEtronIdazoLE) cambridge healthcare Supplies Ltd has extended the anabact 0.75% w/w gel range to include a new 40g pack size, encouraging cost effective dispensing options and nhS cost savings of up to 54% across the range. already available in 15g and 30g sizes, the addition of the 40g tube also offers flexibility for prescribing and dispensing.
the only metronidazole gel indicated for the treatment of malodorous fungating tumours, gravitational, and decubitus ulcers, anabact 0.75% w/w gel is available on prescription (Pom), and is listed on medicines formularies nationwide. available to order from your preferred wholesaler:
40g PIP code: 404-4772 30g PIP code: 224-0083 15g PIP code: 224-0075
for more information visit
www.cambridge-healthcare.co.uk tel: 01953 607856 Email:
enquiries@cambridge-healthcare.co.uk
rEadY-to-USE EPIStatUS® 10 mg oromUcoSaL SoLUtIon mIdazoLam - marKEtIng aUthorISatIon grantEd
27th april 2017: Special Products Ltd is pleased to announce that Epistatus® 10 mg oromucosal Solution, midazolam, has been granted a UK marketing authorisation for use in the treatment of prolonged, acute convulsive seizures in children and adolescents aged 10 to less than 18 years, who have been diagnosed with epilepsy. buccal midazolam is recommended by nIcE for the management of prolonged acute convulsive seizures, and is preferred by most patients and carers compared to the administration of rectal diazepam.
Epistatus is presented “ready-to-use” in a novel, pre-filled, single-dose syringe, to provide carers with the confidence that they are administering the correct dose. the pre-filled syringe is contained within a specially- designed, secure and tamper-evident protective packaging.
In response to market research and insights, Special Products Ltd has invested heavily in the development of this new bespoke syringe, which is designed for administration into the buccal cavity. the granting of this marketing authorisation represents an important milestone for Special Products Ltd, for whom Epistatus is their first licensed product.
the ready-to-use Epistatus pre-filled syringe will be available to prescribe from august 2017, further information to follow. for more information about ordering please contact Special Products Limited on (01932) 690325.
for SaLE
NORTH ANTRIM PHARMACY
Located in a busy health centre
Expressions of interest to be emailed to
ian@irwindonagheystockman.com
PharmacY In focUS - 43
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56
